This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||PTX / Pernix Therapeutics Holdings, Inc. (71426V108)|
|Chairman of the Board & CEO||Sedor John A|
|Institutional Shares||2,268,726 - 19.11%|
|Common Shares Outstanding||11,873,562 shares (as of 2018-03-31)|
|Institutional Value||$ 5,341,000 USD|
71426VAK4 / Pernix Therapeutics Holdings, Inc. Convertible Debt 4.25%|
71426VAJ7 / Pernix Therapeutics Holdings, Inc. Debt 4.25%
Institutional Stock Ownership and Shareholders()
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has 39 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,268,726 shares.
Largest shareholders include
Renaissance Technologies LLC, Vanguard Group Inc, Aisling Capital LLC, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Jacobs Levy Equity Management, Inc, Bank Of Montreal /can/, Bank Of Montreal /can/, Cetera Investment Advisers, and Virtu Financial LLC.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ptx"><img src="https://images.fintel.io/us-ptx-so.png" alt="PTX / Pernix Therapeutics Holdings, Inc. Institutional Ownership"><a>
|BANK OF MONTREAL /CAN/||3,000||63,000||2,000.00||7||153||2,085.71|
|JACOBS LEVY EQUITY MANAGEMENT, INC||73,421||79,921||8.85||176||191||8.52|
|SIMPLEX TRADING, LLC||Call||28||4||-85.71||0||0|
|VANGUARD GROUP INC||327,490||373,449||14.03||786||892||13.49|
|GEODE CAPITAL MANAGEMENT, LLC||39,813||39,595||-0.55||95||94||-1.05|
|Bedel Financial Consulting, Inc.||7||7||0.00||0||0|
|GROUP ONE TRADING, L.P.||Put||0||1,500||0||4|
|Virtu Financial LLC||46,610||111|
|BANK OF AMERICA CORP /DE/||96||1,102||1,047.92||0||3|
|SIMPLEX TRADING, LLC||Put||0||1||0||0|
|BlackRock Advisors LLC||7,631||763||-90.00||5||1||-80.00|
|BlackRock Institutional Trust Company, N.A.||1,610,542||161,054||-90.00||1,002||312||-68.86|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||82,838||0||-100.00||199||0||-100.00|
|WOLVERINE TRADING, LLC||Put||15,400||15,900||3.25||37||38||2.70|
|Stratos Wealth Partners, LTD.||5||0|
|Cetera Investment Advisers||46,750||46,750||0.00||112||112||0.00|
|Evercore Wealth Management, LLC||5||0||-100.00||0||0|
|JP Morgan Chase & Co||100||0||-100.00||0||0|
|WELLS FARGO & COMPANY/MN||176||176||0.00||0||0|
|LADENBURG THALMANN FINANCIAL SERVICES INC||14||14||0.00||0||0|
|CITADEL ADVISORS LLC||Call||11,500||15,700||36.52||28||38||35.71|
|BANK OF MONTREAL /CAN/||Put||3,000||63,000||2,000.00||7||153||2,085.71|
|NORTHERN TRUST CORP||12,535||12,435||-0.80||30||29||-3.33|
|BOOTHBAY FUND MANAGEMENT, LLC||10,330||0||-100.00||25||0||-100.00|
|GROUP ONE TRADING, L.P.||Call||1,100||5,400||390.91||3||13||333.33|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||Put||17,700||0||-100.00||42||0||-100.00|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||33,742||15,124||-55.18||81||36||-55.56|
|WOLVERINE TRADING, LLC||Call||19,900||0||-100.00||48||0||-100.00|
|SEI INVESTMENTS CO||0||5||0||0|
|MetLife Securities, Inc||123||13||-89.43||0||0|
|Searle & Co.||13,325||13,325||0.00||32||32||0.00|
|VALLEY NATIONAL ADVISERS INC||6||6||0.00||0||0|
|CITADEL ADVISORS LLC||Call||15,700||38|
|ARMISTICE CAPITAL, LLC||21,760,000||0||-100.00||9,175||0||-100.00|
|Advisor Group, Inc.||177||177||0.00||0||0|
|UBS Group AG||1,638||6,516||297.80||4||16||300.00|
|Renaissance Technologies LLC||914,750||941,250||2.90||2,195||2,250||2.51|
|GROUP ONE TRADING, L.P.||13,120||9,585||-26.94||31||23||-25.81|
|Aisling Capital LLC||210,000||210,000||0.00||504||502||-0.40|
|ROYAL BANK OF CANADA||103||103||0.00||0||0|
|DEUTSCHE BANK AG\||1||1||0.00||0||0|
|SIMPLEX TRADING, LLC||0||1,703||0||4|
|Shanda Payment Holdings Ltd.||1,000||1,000||0.00||2||2||0.00|
|GOLDMAN SACHS GROUP INC||14,897||15,701||5.40||36||38||5.56|
|Nelson, Van Denburg & Campbell Wealth Management Group, LLC||70||70||0.00||0||0|
|BlackRock Fund Advisors||135,144||17,315||-87.19||84||34||-59.52|
|IFP Advisors, Inc||250||250||0.00||1||1||0.00|
|NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO||0||7||0||0|
2017-10-16 - Asif
Pernix Therapeutics is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its strategy is to continue to create shareholder value by: growing sales of the existing products in its portfolio in various ways, including identifying new growth opportunities; and acquiring additional marketed specialty products or products close to regulatory approval to leverage its existing expertise and infrastructure. Pernix Therapeutics target underserved segments, such as central nervous system (CNS) indications, including neurology, pain and psychiatry. The company promote its core branded products to physicians through its sales forces. The company market its generic products through its wholly owned subsidiaries, Macoven and Cypress. Its branded products include Treximet, a medication indicated for the acute treatment of migraine attacks, with or without aura, ...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Pernix Therapeutics Holdings, Inc. (NYSEMKT:PTX) Q1 2018 Earnings Conference Call May 10, 2018 4:30 PM ET (28-1)
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash. (28-6)
* PERNIX THERAPEUTICS ANNOUNCES PARTICIPATION IN LEAD BID FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS (21-0)
* PERNIX THERAPEUTICS HOLDINGS - EXPECTS TO RESUME DISTRIBUTION OF 20 MG DOSAGE STRENGTH OF ZOHYDRO ER (HYDROCODONE BITARTRATE) WITH BEADTEK ON MARCH 28 Source text for Eikon: Further company coverage: ([email protected]) (21-1)
as of ET